Alector

Update in progress

ALEC (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Alector, Inc. is a clinical-stage biotechnology company focused on therapies to slow neurodegeneration in the United States. Its pipeline includes Nivisnebart, a human monoclonal antibody; AL137, an anti-amyloid beta antibody in preclinical development for Alzheimer's; and AL050, a GCase enzyme replacement therapy in preclinical development for Parkinson’s and Lewy body dementia in GBA1 mutation patients. It also advances AL064 (tau siRNA), ADP062-ABC (alpha-synuclein siRNA), and ADP065-ABC (NLRP3 siRNA). A collaboration with GlaxoSmithKline targets progranulin-elevating antibodies. Founded 2013, based in South San Francisco.

Company score

Sentiment: -0.39; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.35; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.05; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.11; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.25; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive

Company

MarketNasdaqGS (NMS)
LocationUnited States
CEODr. Arnon Rosenthal Ph.D.
Founded2013
Employees103
Websitewww.alector.com

Identifiers

ISINUS0144421072
FIGIBBG00N0PL198
LEI549300Z8RQOIY1JMHC25
CUSIP014442107
CIK0001653087